摘要
背景与目的组织芯片技术可以高通量地分析标本蛋白。本研究的目的是分析非小细胞肺癌患者HER2蛋白的表达情况及其与化疗疗效和生存的关系。方法将80例非小细胞肺癌患者的病理蜡块制成组织芯片,切片后使用免疫组织化学的方法分析HER2蛋白的表达。结果80例患者中最终有74例可以进行免疫组化分析。全组HER2蛋白阳性率为31.1%(23/74)。其中,HER2蛋白阳性表达组化疗有效率为39.1%,阴性组为51.0%(P=0.345)。HER2蛋白阴性和阳性表达患者的生存时间差异没有统计学意义(P=0.437)。结论使用组织微阵列方法联合免疫组织化学方法分析非小细胞肺癌患者HER2蛋白表达是可行的。HER2蛋白阳性表达组和阴性组之间生存时间差异没有统计学意义。HER2蛋白在非小细胞肺癌中的作用还有待进一步研究。
Background and objective Tissue microarray provides a high throughput tool for protein analysis. The aim of this study is to test the expression of HER2 protein in non-small cell lung cancer （NSCLC） by tissue microarray, and analyze the relationship between HER2 protein expression and chemotherapeutic response rate and survival. Methods Using tissue microarray, HER2 protein expression was detected in patients with advanced NSCI.C by immunohistochemistry. Results Total 80 patients were enrolled in the study. Only 74 patients could be reviewed for HER2 staining. The response rate to chemotherapy in positive and negative HER2 expression groups was 39.1% and 51.0% respectively （P=0. 345）. The survival difference was also not significant between the positive and negative HER2 protein expression groups （P=0. 437）. Conclusion The combination of tissue microarray and immunohistochemistry represents a highly feasible technique for examination of HER2 protein expression in NSCLC. There is no significant difference in survival between positive and negative HER2 expression groups. The role of HER2 protein in NSCLC should be further studied.
出处
《中国肺癌杂志》
CAS
2006年第1期50-54,共5页
Chinese Journal of Lung Cancer
基金
广东省科技计划项目基金(2004B30301006)资助~~
